MarketCap
Facebook
X
Telegram
Tenax Therapeutics EBITDA | TENX
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Tenax Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 1967 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -56.4 M | -19.5 M | -8.23 M | 11.1 M | 32.7 M | 9.86 M | -8.45 M | -6.88 M | -9.19 M | -19.4 M | -13.6 M | -16.5 M | -4.79 M | -7.98 M | -9.95 M | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 32.7 M | -56.4 M | -8.48 M |
Quarterly EBITDA Tenax Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -18.8 M | -16.6 M | - | - | - | - | - | -3.67 M | - | - | 2.12 M | 1.24 M | 1.54 M | - | 2.92 M | 2.86 M | 2.72 M | - | 3.81 M | 1.97 M | 23.8 M | - | 2.23 M | 2.15 M | 2.67 M | - | 2.26 M | 1.82 M | 1.66 M | - | 1.56 M | 1.89 M | 1.23 M | - | 1.32 M | 3.02 M | 3.5 M | - | 4.52 M | 4.68 M | -5.7 M | -3.12 M | -3.03 M | -3.72 M | -3.08 M | -2.41 M | -4.03 M | -4.07 M | -2.38 M | -1.57 M | -2 M | -2.04 M | -1.55 M | -1.86 M | -517 K | -609 K | -1.64 M | 2.75 M | -1.8 M | 2.17 M | 2.52 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 23.8 M | -18.8 M | 15.5 K |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Arbutus Biopharma Corporation
ABUS
|
-37.8 M | $ 4.2 | 0.12 % | $ 805 M |  Canada |
 |
ADC Therapeutics SA
ADCT
|
-121 M | $ 1.51 | 4.51 % | $ 192 M |  Schweiz |
 |
AbbVie
ABBV
|
15.8 B | $ 286.99 | 0.47 % | $ 508 B |  USA |
 |
ACADIA Pharmaceuticals
ACAD
|
106 M | $ 19.75 | 0.08 % | $ 3.33 B | USA |
 |
Artelo Biosciences
ARTL
|
-11.4 M | $ 2.32 | -10.98 % | $ 439 K | USA |
 |
Biofrontera AG
BFRA
|
-2.28 M | - | -8.24 % | $ 105 M |  Germany |
 |
Aquestive Therapeutics
AQST
|
-70.5 M | $ 3.98 | -0.63 % | $ 426 M | USA |
 |
Armata Pharmaceuticals
ARMP
|
-35.1 M | $ 3.46 | -4.95 % | $ 125 M | USA |
 |
Catabasis Pharmaceuticals, Inc.
CATB
|
-37.4 M | - | -6.97 % | $ 657 M | USA |
 |
Atara Biotherapeutics
ATRA
|
38 M | $ 8.31 | -3.26 % | $ 104 M | USA |
 |
China Biologic Products Holdings, Inc.
CBPO
|
223 M | - | 1.68 % | $ 4.65 B |  China |
 |
Autolus Therapeutics plc
AUTL
|
-262 M | $ 1.54 | -0.32 % | $ 410 M |  Britain |
 |
Bicycle Therapeutics plc
BCYC
|
-241 M | $ 3.66 | 3.1 % | $ 254 M | Britain |
 |
BeyondSpring
BYSI
|
-8.86 M | $ 0.47 | 9.77 % | $ 19.3 M | USA |
 |
Flexion Therapeutics, Inc.
FLXN
|
-89.7 M | - | - | $ 459 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
203 M | $ 72.06 | -0.76 % | $ 1.45 B | USA |
 |
Ardelyx
ARDX
|
-37.9 M | $ 3.01 | -2.31 % | $ 726 M | USA |
 |
argenx SE
ARGX
|
1.05 B | $ 866.15 | -0.86 % | $ 53.1 B |  Niderland |
 |
Arvinas
ARVN
|
-116 M | $ 7.28 | -0.34 % | $ 516 M | USA |
 |
Axsome Therapeutics
AXSM
|
-166 M | $ 143.88 | -0.8 % | $ 7.16 B | USA |
 |
Heat Biologics, Inc.
HTBX
|
-24.7 M | - | -5.76 % | $ 99.8 M | USA |
 |
Kindred Biosciences, Inc.
KIN
|
-11 M | - | 0.11 % | $ 419 M | USA |
 |
BioNTech SE
BNTX
|
-1.4 B | $ 86.9 | -1.38 % | $ 21 B | Germany |
 |
Alterity Therapeutics Limited
ATHE
|
-17.3 M | $ 2.1 | 0.48 % | $ 13.4 B |  Australia |
 |
Shineco, Inc.
TYHT
|
-4.38 M | - | -3.90 % | $ 97.2 M | China |
 |
Actinium Pharmaceuticals
ATNM
|
-36.1 M | $ 1.41 | -7.24 % | $ 44 M | USA |
 |
Aytu BioScience
AYTU
|
-4.38 M | $ 1.93 | 1.58 % | $ 23.8 M | USA |
 |
Codexis
CDXS
|
-36.5 M | $ 1.29 | 0.39 % | $ 112 M | USA |
 |
Intec Pharma Ltd
NTEC
|
-12.6 M | - | -12.45 % | $ 17.7 M |  Israel |
 |
Genmab A/S
GMAB
|
6.57 B | $ 44.64 | 1.94 % | $ 2.89 B |  Danmark |
 |
GeoVax Labs
GOVX
|
-21.6 M | $ 0.19 | -7.18 % | $ 182 K | USA |
 |
Cellectar Biosciences
CLRB
|
-22.8 M | $ 1.23 | 0.82 % | $ 3.21 M | USA |
 |
Galectin Therapeutics
GALT
|
-20.1 M | $ 3.19 | -0.31 % | $ 204 M | USA |
 |
GT Biopharma
GTBP
|
-12.4 M | $ 5.17 | -5.31 % | $ 28.5 M | USA |
 |
Progenity, Inc.
PROG
|
-190 M | - | -3.47 % | $ 164 M | USA |
 |
Genprex
GNPX
|
-15.5 M | $ 1.81 | 0.22 % | $ 1.69 M | USA |
 |
Strongbridge Biopharma plc
SBBP
|
-38.1 M | - | 1.52 % | $ 136 M | USA |
 |
Cue Biopharma
CUE
|
-25.6 M | $ 18.45 | -1.1 % | $ 1.75 B | USA |
 |
Seneca Biopharma, Inc.
SNCA
|
-10.6 M | - | -1.19 % | $ 28.7 M | USA |
 |
DiaMedica Therapeutics
DMAC
|
-34.4 M | $ 8.74 | 0.23 % | $ 411 M | USA |
 |
Cardiff Oncology
CRDF
|
-48.6 M | $ 0.81 | -10.82 % | $ 54.1 M | USA |
 |
Inhibrx
INBX
|
-218 M | $ 88.26 | -5.48 % | $ 4.16 B | USA |
 |
Kazia Therapeutics Limited
KZIA
|
-7.74 M | $ 7.91 | 1.28 % | $ 121 M | Australia |
 |
Fate Therapeutics
FATE
|
-135 M | $ 2.06 | -2.61 % | $ 245 M | USA |
 |
Eton Pharmaceuticals
ETON
|
3.2 M | $ 50.15 | 0.3 % | $ 1.35 B | USA |
 |
Fulcrum Therapeutics
FULC
|
-83.4 M | $ 3.65 | -0.95 % | $ 231 M | USA |
 |
Hutchison China MediTech Limited
HCM
|
-25.9 M | $ 14.31 | -0.38 % | $ 12.3 B | China |
 |
IDEAYA Biosciences
IDYA
|
-157 M | $ 33.2 | -4.35 % | $ 2.94 B | USA |
 |
InflaRx N.V.
IFRX
|
-44.9 M | $ 1.57 | 0.32 % | $ 106 M | Germany |